Канада - Енглески - Health Canada

janssen inc - epoetin alfa - solution - 4000unit - epoetin alfa 4000unit - hematopoietic agents

Канада - Енглески - Health Canada

janssen inc - epoetin alfa - solution - 2000unit - epoetin alfa 2000unit - hematopoietic agents

Канада - Енглески - Health Canada

janssen inc - epoetin alfa - solution - 20000unit - epoetin alfa 20000unit - hematopoietic agents

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets, usp are indicated for the treatment of major depressive disorder.  the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders-3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology).  a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation.  the effectiveness of mirtazapine in hospital

Канада - Енглески - Health Canada

teva canada limited - fluconazole - solution - 2mg - fluconazole 2mg - azoles

Канада - Енглески - Health Canada

sandoz canada incorporated - fluconazole - solution - 2mg - fluconazole 2mg - azoles

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

medical purchasing solutions, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - a. intravenous or intramuscular administration . when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. endocrine disorders . primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or

Канада - Енглески - Health Canada

baxter corporation - ceftriaxone (ceftriaxone sodium) - solution - 1000mg - ceftriaxone (ceftriaxone sodium) 1000mg - third generation cephalosporins

Канада - Енглески - Health Canada

baxter corporation - ceftriaxone (ceftriaxone sodium) - solution - 2000mg - ceftriaxone (ceftriaxone sodium) 2000mg - third generation cephalosporins

Канада - Енглески - Health Canada

pharmascience inc - salbutamol (salbutamol sulfate) - solution - 5mg - salbutamol (salbutamol sulfate) 5mg - selective beta 2-adrenergic agonists